JP2012520084A5 - - Google Patents

Download PDF

Info

Publication number
JP2012520084A5
JP2012520084A5 JP2011554266A JP2011554266A JP2012520084A5 JP 2012520084 A5 JP2012520084 A5 JP 2012520084A5 JP 2011554266 A JP2011554266 A JP 2011554266A JP 2011554266 A JP2011554266 A JP 2011554266A JP 2012520084 A5 JP2012520084 A5 JP 2012520084A5
Authority
JP
Japan
Prior art keywords
vector
virus
protein
present
heterologous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011554266A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012520084A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/027262 external-priority patent/WO2010105251A2/en
Publication of JP2012520084A publication Critical patent/JP2012520084A/ja
Publication of JP2012520084A5 publication Critical patent/JP2012520084A5/ja
Withdrawn legal-status Critical Current

Links

JP2011554266A 2009-03-13 2010-03-13 非組み込み型レトロウイルスベクターワクチン Withdrawn JP2012520084A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US16028509P 2009-03-13 2009-03-13
US61/160,285 2009-03-13
US16676909P 2009-04-05 2009-04-05
US61/166,769 2009-04-05
US16708809P 2009-04-06 2009-04-06
US61/167,088 2009-04-06
PCT/US2010/027262 WO2010105251A2 (en) 2009-03-13 2010-03-13 Non-integrating retroviral vector vaccines

Publications (2)

Publication Number Publication Date
JP2012520084A JP2012520084A (ja) 2012-09-06
JP2012520084A5 true JP2012520084A5 (enExample) 2013-04-25

Family

ID=42729161

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011554266A Withdrawn JP2012520084A (ja) 2009-03-13 2010-03-13 非組み込み型レトロウイルスベクターワクチン

Country Status (7)

Country Link
US (1) US20120135034A1 (enExample)
EP (1) EP2405945A4 (enExample)
JP (1) JP2012520084A (enExample)
CN (1) CN102438658A (enExample)
CA (1) CA2754603A1 (enExample)
RU (1) RU2012140691A (enExample)
WO (1) WO2010105251A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2013139565A (ru) * 2011-01-27 2015-03-10 Лентиджен Корпорейшн Усовершенствованная праймерная и бустерная вакцина
AU2012267512B2 (en) 2011-06-10 2014-11-20 Bluebird Bio, Inc. Gene therapy vectors for adrenoleukodystrophy and adrenomyeloneuropathy
US9713635B2 (en) * 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
DK2831095T3 (en) * 2012-03-30 2019-02-18 Immune Design Corp LENTIVIRAL VECTOR PARTICLES WITH IMPROVED TRANSDUCTION EFFICIENCY FOR CELL EXPRESSING DC SIGN
JP6640717B2 (ja) * 2013-06-15 2020-02-05 トカジェン インコーポレーテッド レトロウイルス複製ベクターと関連する免疫抑制成分
EP2878674A1 (en) * 2013-11-28 2015-06-03 Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) Stable episomes based on non-integrative lentiviral vectors
EP3137100B1 (en) 2014-04-15 2023-12-20 University Of Virginia Patent Foundation Isolated t cell receptors and methods of use therefor
MA41382A (fr) * 2015-03-20 2017-11-28 Univ Temple Édition génique basée sur le système crispr/endonucléase à induction par tat
EP3270960A4 (en) * 2015-03-20 2018-08-08 Bluebird Bio, Inc. Vector formulations
WO2017066570A1 (en) * 2015-10-15 2017-04-20 The University Of North Carolina At Chapel Hill Methods and compositions for integration-defective lentiviral vectors
EP3426353A4 (en) * 2016-03-09 2020-05-06 The University of Massachusetts USE OF MODIFIED HIV-1 TO GENERATE FULLY HUMAN ANTIBODIES
GB201715052D0 (en) * 2017-09-19 2017-11-01 Oxford Genetics Ltd Vectors
US20200390877A1 (en) 2017-12-07 2020-12-17 Merck Sharp & Dohme Corp. Formulations of dengue virus vaccine compositions
RU2680703C1 (ru) * 2018-02-13 2019-02-25 Общество с ограниченной ответственностью "Нанолек" Кассета, предназначенная для получения плазмидных векторов, используемых для создания клеток-продуцентов вирусоподобных частиц (ВПЧ) вируса гриппа
RU2680537C1 (ru) * 2018-02-13 2019-02-22 Общество с ограниченной ответственностью "Нанолек" Лентивирусная плазмида (варианты), способ ее получения (варианты), набор праймеров для получения лентивирусного плазмидного вектора (варианты)
RU2681439C1 (ru) * 2018-02-13 2019-03-06 Общество с ограниченной ответственностью "Нанолек" Вирусоподобная частица вируса гриппа и способ ее получения
RU2681482C1 (ru) * 2018-02-13 2019-03-06 Общество с ограниченной ответственностью "Нанолек" MDCK клетка-продуцент белков вируса гриппа (варианты)
WO2020018715A1 (en) 2018-07-17 2020-01-23 Massachusetts Institute Of Technology Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
EP3886759A1 (en) 2018-11-26 2021-10-06 Massachusetts Institute of Technology Compositions and methods for immune tolerance
CN114258398A (zh) 2019-06-13 2022-03-29 总医院公司 工程化的人内源性病毒样颗粒及使用其递送至细胞的方法
CN116670154A (zh) 2020-07-24 2023-08-29 总医院公司 增强的病毒样颗粒及使用其递送至细胞的方法
US11992524B2 (en) * 2021-10-25 2024-05-28 Genvivo, Inc. Compositions and methods for therapeutic or vaccine delivery

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998046083A1 (en) * 1997-04-17 1998-10-22 The Regents Of The University Of California Use of lentiviral vectors for antigen presentation in dendritic cells
US5994136A (en) * 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
WO2004029246A2 (en) * 2002-09-26 2004-04-08 K.U.Leuven Research And Development Integrase cofactor
GB0225786D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
EP2055316A1 (en) * 2003-09-09 2009-05-06 VIRxSYS Corporation Lentivirus vector-based approaches for generating an immune response to HIV in humans
AU2004279362B2 (en) * 2003-09-15 2011-03-17 Genvec, Inc. HIV vaccines based on ENV of multiple clades of HIV
FR2872170B1 (fr) * 2004-06-25 2006-11-10 Centre Nat Rech Scient Cnrse Lentivirus non interactif et non replicatif, preparation et utilisations
WO2006058231A2 (en) * 2004-11-24 2006-06-01 Nanovector Limited Viral vectors
MX2007010008A (es) * 2005-02-16 2008-01-18 Lentigen Corp Vectores lentivirales y su uso.
GB0526211D0 (en) * 2005-12-22 2006-02-01 Oxford Biomedica Ltd Viral vectors
EP2020444B1 (en) * 2007-08-03 2017-05-31 Institut Pasteur Defective non-integrative lentiviral transfer vectors for vaccines

Similar Documents

Publication Publication Date Title
US20120135034A1 (en) Non-Integrating Retroviral Vector Vaccines
CN110958887B (zh) 编码hiv抗原的痘病毒载体及其使用方法
JP2018076363A (ja) レンチウイルス遺伝子導入ベクター及びそれらの医薬品への適用
JP2013027396A (ja) クレードＡ／Ｇ、クレードＢ、およびクレードＣ改変ＨＩＶｅｎｖ、ｇａｇ、およびｐｏｌ遺伝子を発現する組換えＭＶＡウイルス
Di Nunzio et al. HIV-derived vectors for therapy and vaccination against HIV
US20110142880A1 (en) Lentivirus-based immunogenic vectors
CN104039968B (zh) 非b亚型gag蛋白在慢病毒包装中的应用
JP2024502658A (ja) 麻疹－ｈｉｖ又は麻疹－ｈｔｌｖワクチン
CA2825032A1 (en) Advanced prime and boost vaccine
EP1543837A1 (en) Virus-like particle (VLP) as vaccine
RU2697781C2 (ru) Вспомогательный плазмидный лентивирусный экспрессионный вектор для получения высоких титров vpx-содержащих лентивирусных частиц, обеспечивающий эффективное заражение моноцитов и дендритных клеток человека
Wang et al. Polyvalent DNA prime and envelope protein boost HIV‐1 vaccine elicits humoral and cellular responses and controls...
McKenna Characterization and immunogenicity of recombinant rhabdoviral vaccine vectors expressing HIV-1 and SIV envelope proteins
HK1200870B (en) Use of non-subtype b gag proteins for lentiviral packaging